Study monitoring during CMT
toxicity, toxicities
ADVERSE EVENTS
Patients will be closely followed throughout the study and evaluated at each CMT session to monitor adverse events. Complete physical examination, toxicity assessment, and hematological analysis were conducted on D1 and D8 of each cycle. Patients with Grade 3 and Grade 4 toxicity will have their treatment suspended until resolution to Grade 1. CMT will be restarted according to the judgment of the clinical oncologist responsible for the case, and a 20% dose reduction will be recommended, at the investigator's discretion. Follow-up for adverse events will occur for 30 days after the last dose of XP, or until all serious or study-related toxicities are resolved or determined to be chronic or stable.